Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of LY4050784 to treat advanced solid tumors. The people in this study have cancer that cannot be cured with standard therapies. Their tumors also have a mutation (change) in the SMARCA4 and/or BRG1 genes, which play a role in cancer growth.
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.
Researchers are assessing the combination of teclistamab and mezigdomide to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment.
People with cancer often complain that their "mind does not seem to be clear." This can be due to stress, depression or anxiety, or physical problems, or may be due to some cancer treatments. The purpose of this study is to better understand the effects of cancer treatments on thinking (cognitive) abilities and memory in people with breast cancer over age 60. Thinking abilities and memory may decrease with age, and the effects of some treatments could make this problem worse in older people with breast cancer.
In this study, researchers want to find the highest dose of the drug abemaciclib that can be given safely with ruxolitinib in people with myelofibrosis that has developed on its own (primary myelofibrosis) or as a complication of the blood diseases polycythemia vera or essential thrombocythemia. In people with myelofibrosis, the bone marrow is not able to make enough blood cells. The spleen is bigger than normal, making the stomach feel very full. Patients may also have fever and night sweats.
This study is assessing a blood test that may tell doctors which people need immunotherapy after bladder cancer surgery. Many types of tumors lose cells into the bloodstream and shed their DNA. This circulating tumor DNA (ctDNA) may be found before changes in a tumor can be seen on scans.
Idecabtagene vicleucel is a form of CAR T immunotherapy for multiple myeloma. People who have this treatment are usually monitored (watched) afterward, with no additional myeloma medications. In this study, researchers want to see if giving iberdomide as maintenance therapy after idecabtagene vicleucel is better than monitoring.
Researchers want to see if adding zanidatamab to standard treatment works well against biliary tract cancer. The people in this study have biliary tract cancer that has spread or cannot be removed with surgery. In addition, their cancers make a protein called HER2.
Intensity-modulated pleural radiation therapy (IMPRINT) is a type of radiation therapy that specifically targets the lining of the lungs and the inner side of the ribs to stop cancer from growing. In this study, researchers are studying the safety and effectiveness of IMPRINT to one side of the chest (hemithoracic IMPRINT) to treat people with thymic cancer (cancer of the thymus gland) that has spread to the lining of the lungs and chest.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread).
